Goldman Sachs Group Inc. Trims Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Goldman Sachs Group Inc. lowered its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 10.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 211,873 shares of the company’s stock after selling 24,271 shares during the period. Goldman Sachs Group Inc. owned approximately 0.18% of Trevi Therapeutics worth $1,333,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of TRVI. Vanguard Group Inc. boosted its stake in shares of Trevi Therapeutics by 9.4% in the first quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company’s stock valued at $24,141,000 after purchasing an additional 328,819 shares during the period. MPM Bioimpact LLC boosted its holdings in shares of Trevi Therapeutics by 10.8% in the 1st quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company’s stock valued at $21,564,000 after buying an additional 333,470 shares in the last quarter. Octagon Capital Advisors LP acquired a new stake in shares of Trevi Therapeutics during the first quarter worth about $20,895,000. Armistice Capital LLC purchased a new position in Trevi Therapeutics during the 1st quarter worth approximately $18,795,000. Finally, Acorn Capital Advisors LLC increased its stake in Trevi Therapeutics by 7.2% in the first quarter. Acorn Capital Advisors LLC now owns 2,144,844 shares of the company’s stock valued at $13,491,000 after purchasing an additional 143,796 shares during the period. 95.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently weighed in on TRVI. Raymond James Financial lowered their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, June 6th. D. Boral Capital restated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Finally, HC Wainwright began coverage on shares of Trevi Therapeutics in a research report on Wednesday, May 28th. They set a “buy” rating and a $21.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $21.75.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $8.15 on Friday. The firm has a market cap of $992.51 million, a P/E ratio of -19.40 and a beta of 0.71. Trevi Therapeutics, Inc. has a 1-year low of $2.36 and a 1-year high of $9.92. The firm’s 50-day simple moving average is $7.56 and its 200-day simple moving average is $6.66.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.